No headlines found.
Globe Newswire (Thu, 19-Feb 8:00 AM ET)
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI).
Cocrystal Pharma trades on the NASDAQ stock market under the symbol COCP.
As of March 2, 2026, COCP stock price was flat at $1.05 with 38,417 million shares trading.
COCP has a beta of 0.47, meaning it tends to be less sensitive to market movements. COCP has a correlation of 0.02 to the broad based SPY ETF.
COCP has a market cap of $14.47 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, COCP traded as high as $3.29 and as low as $.86.
The top ETF exchange traded funds that COCP belongs to (by Net Assets): VTI, VXF.
COCP has underperformed the market in the last year with a return of -39.3%, while SPY returned +16.7%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in COCP shares. However, COCP has outperformed the market in the last 3 month and 2 week periods, returning +4.0% and +8.8%, while SPY returned +1.0% and +0.7%, respectively. This indicates COCP has been having a stronger performance recently.
COCP support price is $.99 and resistance is $1.11 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that COCP shares will trade within this expected range on the day.
